Delving into the Latest Updates on DUOFAG with Synapse

Overview

Basic Info

Drug Type

Bacteriophage therapy

Synonyms

DUOFAG

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication

Bacterial InfectionsWounds and InjuriesPseudomonas aeruginosa infection+ [3]

Inactive Indication-

Originator Organization

MB Pharma S.R.O.

Active Organization

MB Pharma S.R.O.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Login to view timeline

DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S. aureus and P. aeruginosa.
The primary objective of the study is to demonstrate the safety of DUOFAG® and the clinical and microbiological change within 10 weeks after the start of treatment or until healing.

Start Date27 Oct 2023

Sponsor / Collaborator

MB Pharma S.R.O.

100 Clinical Results associated with DUOFAG

Login to view more data

100 Translational Medicine associated with DUOFAG

Login to view more data

100 Patents (Medical) associated with DUOFAG

Login to view more data

100 Deals associated with DUOFAG

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial Infections	Phase 3	Czechia	MB Pharma S.R.O.	01 Jan 2026
Wounds and Injuries	Phase 3	Czechia	MB Pharma S.R.O.	01 Jan 2026
Pseudomonas aeruginosa infection	Phase 2	Czechia	MB Pharma S.R.O.	27 Oct 2023
Staphylococcus Aureus Infections	Phase 2	Czechia	MB Pharma S.R.O.	27 Oct 2023
Surgical Wound Infection	Phase 2	Czechia	MB Pharma S.R.O.	27 Oct 2023
Surgical Wound	Phase 2	Czechia	MB Pharma S.R.O.	02 Oct 2023